JITTERBIT
9.11.2021 09:02:10 CET | Business Wire | Press release
Jitterbit, the API transformation company, has revealed its first ever Integration Trends Report. It gives an unparalleled view of how companies responded to the seismic challenges of the global pandemic - and how they are building back stronger.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211109005727/en/
Analysing anonymised data of over 2,000 customers across EMEA from 2020 - 2021, the report reveals macro trends across markets as companies innovated to meet rapidly changing customer needs, move more of their services online and enable remote working for employees.
“The trends emerging all point to a need to move quickly and provide the highest level of product, service and employee experience in order to compete and survive, with companies turning to no-code/ low-code and microservices in readiness for the next stage of hypergrowth. ” said Steve Sichtman, VP Multi Channel Development, Jitterbit
Rather than freeze or reduce spend on integrating new technologies, companies actively sought to spend more on integration across a number of key areas:
Service Experience and eCommerce Spend
- With many physical locations closed or severely disrupted in 2020 and unprecedented customer demand for online service, companies responded by increasing their eCommerce integration investment by 99% during the year.
- Companies increased spend on Services Experience 360 on average by 50% in 2020. Growth in the services front-end with applications such as BMC Helix ITSM, Jira, Zendesk and others was also matched with growth in the services back-end around IT operations.
Product Experience
- Companies increased their spend on Product 360 (optimizing the product life cycle) in 2020 by 26%.
- Data from 2020 reveals a double digit increase in demand around large ERP systems from vendors like SAP and Microsoft. Optimizing business processes was a key focus as businesses realized the essential value of having automated processes across the entire manufacturing, supply chain and sales processes.
Employee Experience
- Companies increased their spend on Employee Experience 360 in 2020 by 72%. Increased reliance on a remote workforce, new communications tools, and fluctuating budgets all contributed to this increased focus on employee experience.
Low-code, microservice and marketplace popularity
- Low-code and no-code gained popularity because of the many hyper automation benefits it offers to IT teams, becoming in the process a key differentiator when selecting an integration platform-as-a-service (iPaaS).
- Many companies have already moved to microservices, rather than API, architecture. Self-contained and ready to go, microservices can be plugged into a wide array of applications and leveraged throughout an organization. Now, there’s evidence of increased demand for iPaaS systems that work closely with microservices. This empowers business users to plug different microservices together to create specialized applications without no-code.
- Many Enterprise and Software companies are finding it’s no longer sufficient to offer an API for the outside world to connect to them. They must overcome the “integration burden” to improve retention and stickiness. The answer lies in integration marketplaces where companies can offer pre-built and certified API integrations and solutions to their partners and customers.
This Integration Trends report demonstrates how trends in integration technology - the way modern businesses automate the connections between the myriad softwares, platforms and technologies they deploy - reflect how businesses respond to meet the macro challenges and opportunities they face.
The report also provides actionable insights on what businesses now need to focus on as countries across EMEA move into the post-pandemic period.
To download the full report, visit: https://info.jitterbit.com/jitterbit-trends-report.html
Ends.
About Jitterbit, Inc.
Jitterbit, the API transformation company, makes it quicker and easier for businesses to exploit data from any source, empowering them to rapidly innovate and make faster, more effective decisions. The Jitterbit Harmony API integration platform and API360 solutions enable companies to quickly connect SaaS, on-premises, and cloud applications and instantly infuse intelligence into any business process. To learn more, visit www.jitterbit.com or follow us on LinkedIn and on Twitter at @Jitterbit .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211109005727/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom